The PROMISE of Ending Perinatal Mother-to-Child HIV Transmission

Combination antiretroviral therapy was associated with lower risk for maternal-child transmission than AZT alone, but with a higher rate of preterm births.

To understand the efficacy and safety of three antiretroviral strategies to prevent mother-to-child HIV transmission, investigators conducted a randomized open-label study in seven countries (six in sub-Saharan Africa, plus India). The regimens compared were:

AZT during pregnancy plus intrapartum, singe-dose nevirapine with a short postpartum course of tenofovir plus FTC (AZT-alone arm)
AZT/lamivudine plus lopinavir–ritonavir (AZT-based ART)
Tenofovir/FTC plus lopinavir–r (tenofovir-based ART)

All infants in the combination arms also received nevirapine.

Among 3490 mother-infant sets analyzed, there were 3202 live births. The primary efficacy outcome of early HIV transmission (through week 1 after delivery) was low in all groups but was lower in…

Reviewing Author

Carlos del Rio, MD

Disclosures

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines

Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)